Patents by Inventor Rodger Henry

Rodger Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salt and crystalline forms thereof of a drug
    Patent number: 10329276
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: June 25, 2019
    Assignee: ABBVIE INC.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG
    Publication number: 20180105510
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: December 18, 2017
    Publication date: April 19, 2018
    Inventors: Geoff G.Z. ZHANG, Michael F. BRADLEY, David M. BARNES, Rodger HENRY
  • Salt and crystalline forms thereof of a drug
    Patent number: 9873681
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: January 23, 2018
    Assignee: ABBVIE INC.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG
    Publication number: 20170073329
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Inventors: Geoff G.Z. ZHANG, Michael F. BRADLEY, David M. BARNES, Rodger HENRY
  • Salt and crystalline forms thereof of a drug
    Patent number: 9539250
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 10, 2017
    Assignee: ABBVIE INC.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Salt and Crystalline Forms Thereof of a Drug
    Publication number: 20150196547
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: February 3, 2015
    Publication date: July 16, 2015
    Inventors: Geoff G.Z. ZHANG, Michael F. BRADLEY, David M. BARNES, Rodger HENRY
  • Salt and crystalline forms thereof of a drug
    Patent number: 8969569
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: March 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Salt and Crystalline Forms Thereof of a Drug
    Publication number: 20140155380
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: ABBVIE INC.
    Inventors: Geoff G.Z. ZHANG, Michael F. BRADLEY, David M. BARNES, Rodger HENRY
  • Salt and crystalline forms thereof of a drug
    Patent number: 8648093
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: February 11, 2014
    Assignee: Abbvie Inc.
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Salt and Crystalline Forms Thereof of a Drug
    Publication number: 20130060040
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: August 27, 2012
    Publication date: March 7, 2013
    Applicant: ABBOTT LABORATORIES
    Inventors: Geoff G.Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Salt of ABT-263 and solid-state forms thereof
    Patent number: 8362013
    Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: January 29, 2013
    Assignee: AbbVie Inc.
    Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G. Z. Zhang, Deliang Zhou
  • Salt and crystalline forms thereof of a drug
    Patent number: 8273892
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: September 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Salt and crystalline forms thereof of a drug
    Patent number: 8252813
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: August 28, 2012
    Assignee: Abbott Laboratories
    Inventors: Geoff G. Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry
  • Methods of Manufacturing Crystalline Forms of Rapamycin Analogs
    Publication number: 20120028908
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Application
    Filed: October 1, 2011
    Publication date: February 2, 2012
    Applicant: Abbott Laboratories
    Inventors: Shekhar VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Methods of manufacturing crystalline forms of rapamycin analogs
    Patent number: 8034926
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 11, 2011
    Assignee: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • Crystalline forms of rapamycin analogs
    Patent number: 8030326
    Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 4, 2011
    Assignee: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS
    Publication number: 20110009325
    Abstract: Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Abbott Laboratories
    Inventors: SHEKHAR VISWANATH, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • METHODS OF MANUFACTURING CRYSTALLING FORMS OF RAPAMYCIN ANALOGS
    Publication number: 20110009618
    Abstract: A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 13, 2011
    Applicant: Abbott Laboratories
    Inventors: Shekhar Viswanath, Larry Bartelt, Robert Leanna, Michael Rasmussen, Madhup Dhaon, Rodger Henry, Thomas Borchardt, Shuang Chen, Geoff Zhang
  • SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF
    Publication number: 20100305125
    Abstract: ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 2, 2010
    Inventors: Thomas Borchardt, Paul Brackemeyer, Nathaniel Catron, Rodger Henry, Xiaochun Lou, Matthew Ravn, Geoff G.Z. Zhang, Deliang Zhou
  • SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG
    Publication number: 20100286397
    Abstract: A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
    Type: Application
    Filed: April 20, 2010
    Publication date: November 11, 2010
    Inventors: Geoff G.Z. Zhang, Michael F. Bradley, David M. Barnes, Rodger Henry